### BEFORE THE

### INDEPENDENT CITIZENS' OVERSIGHT COMMITTEE TO THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE ORGANIZED PURSUANT TO THE CALIFORNIA STEM CELL RESEARCH AND CURES ACT

## REGULAR MEETING

LOCATION: VARIOUS NOTICED SITES

- DATE: FRIDAY, SEPTEMBER 14, 2007 3 P.M.
- REPORTER: BETH C. DRAIN, CSR CSR. NO. 7152

BRS FILE NO.: 79494

# INDEX

ITEM	DESCRIPTION	PAGE	NO.
CALL TO O	RDER		3
ROLL CALL			3
CLOSED SE	SSION (NOT REPORTED)		6
PUBLIC RE	PORT OF ACTION TAKEN		7
PUBLIC CO	MMENT	1	L1
ADJOURNME	NT	1	L6

1	FRIDAY, SEPTEMBER 14, 2007
2	3 P.M.
3	
4	CHAIRMAN KLEIN: OKAY. WE'D LIKE TO SEE
5	PRELIMINARILY HOW MANY BOARD MEMBERS HAVE JOINED THE CALL
6	AT THIS TIME. SO THIS IS BOB KLEIN. I'M OPENING THE
7	MEETING BY ASKING MELISSA KING TO PLEASE GO THROUGH THE
8	ROLL AND SEE WHO WE HAVE PRESENT.
9	MS. KING: RICARDO AZZIZ. DAVID MEYER FOR
10	RICARDO AZZIZ. ROBERT PRICE.
11	DR. PRICE: HERE.
12	MS. KING: DAVID BRENNER. SUSAN BRYANT.
13	MARSHA CHANDLER. MARCY FEIT. MICHAEL FRIEDMAN.
14	DR. FRIEDMAN: HERE.
15	MS. KING: MICHAEL GOLDBERG.
16	MR. GOLDBERG: HERE.
17	MS. KING: BRIAN HENDERSON. DAVID KESSLER.
18	BOB KLEIN.
19	CHAIRMAN KLEIN: HERE.
20	MS. KING: SHERRY LANSING. GERALD LEVEY.
21	DR. LEVEY: HERE.
22	MS. KING: TED LOVE.
23	DR. LOVE: HERE.
24	MS. KING: TINA NOVA. ED PENHOET. PHIL PIZZO.
25	CLAIRE POMEROY.

3

1 DR. POMEROY: HERE. 2 MS. KING: FRANCISCO PRIETO. 3 DR. PRIETO: HERE. 4 MS. KING: JEANNIE FONTANA. DUANE ROTH. 5 MR. ROTH: HERE. 6 MS. KING: JOAN SAMUELSON. DAVID 7 SERRANO-SEWELL. JEFF SHEEHY. 8 MR. SHEEHY: HERE. 9 MS. KING: JONATHAN SHESTACK. OSWALD STEWARD. 10 JANET WRIGHT. 11 DR. WRIGHT: HERE. 12 MS. KING: AND I WILL CIRCLE BACK THROUGH 13 BECAUSE I KNOW SOMEONE ELSE JOINED AND IN CASE ANYONE WAS 14 MUTED. 15 RICARDO AZZIZ. BRIAN HENDERSON. DAVID 16 KESSLER. SHERRY LANSING. TINA NOVA. ED PENHOET. PHIL 17 PIZZO. JOHN REED. JOAN SAMUELSON. DAVID 18 SERRANO-SEWELL. JONATHAN SHESTACK. OSWALD STEWARD. 19 CHAIRMAN KLEIN: ALL RIGHT. AND DO WE HAVE OUR 20 COUNSEL ON THE PHONE? IS JAMES HARRISON AND IS TAMAR 21 PACHTER ON THE PHONE? 22 MS. PACHTER: YES. WE'RE BOTH HERE. 23 CHAIRMAN KLEIN: OKAY. THANK YOU. JAMES AND TAMAR, MY UNDERSTANDING IS THAT WE CAN OPEN THIS MEETING. 24 25 AND MY QUESTION FOR YOU IS DO I NEED TO OPEN IT TO HAVE A 4

QUORUM; OR IF THE QUORUM COMES ON DURING OUR MEETING,
 THEN, AS LONG AS WE HAVE A QUORUM BEFORE WE TAKE ANY
 ACTION, IS THAT SUFFICIENT?

4 MR. HARRISON: THAT'S RIGHT. YOU CAN OPEN THE 5 SESSION. YOU CAN'T OBVIOUSLY TAKE ANY ACTION WITHOUT A 6 QUORUM, BUT YOU CAN OPEN THE SESSION.

CHAIRMAN KLEIN: OKAY. SO WE WILL BE OPENING 7 8 THE SESSION TODAY. MEETING TODAY BY THE BOARD IS TO 9 CONTINUE THE PRESIDENTIAL SEARCH PROCESS. IT IS A SEARCH 10 OF GLOBAL TALENT. IT IS A SEARCH OF THE BEST IN THIS 11 COUNTRY AND AROUND THE WORLD TO FIND THE RIGHT INDIVIDUAL 12 FOR THE SCIENTIFIC VISION TO LEAD IN A PARTICIPATORY 13 PARTNERSHIP WITH THE BOARD TO BRING THIS AGENCY TO ITS GREATEST POTENTIAL IN THE MISSION OF MEDICAL RESEARCH, 14 15 FIRST SEARCHING FOR STEM CELL CURES AND THERAPIES FOR 16 CHRONIC DISEASE AND INJURY.

AT THIS TIME WHAT WE'RE GOING TO DO IS ADJOURN TO THE EXECUTIVE SESSION, AND WE WILL DO A ROLL CALL WHEN WE RECONVENE TO INDICATE WHICH MEMBERS HAVE JOINED AT THAT TIME PERIOD SO THAT IT IS VERY CLEAR IF WE TAKE ANY ACTION, IF WE TAKE ANY ACTION TODAY, THE MEMBERS THAT ARE PARTICIPATING.

DR. LEVEY: WE DIAL THE SAME NUMBER, BOB?
MS. KING: YES. YOU HAVE IT AND IF YOU DON'T,
PLEASE CALL ME ON MY CELL PHONE AT (415) 816-1051 AND

5

1 I'LL GIVE IT TO YOU, BUT YOU SHOULD HAVE IT IN AN E-MAIL. 2 CHAIRMAN KLEIN: WHY DON'T YOU REPEAT THAT 3 NUMBER, PLEASE. 4 MS. KING: SURE. MY CELL PHONE NUMBER IS (415) 5 816-1051. PLEASE CALL ME ON THAT NUMBER IF YOU NEED THE 6 CLOSED SESSION DIAL-IN NUMBER. THANK YOU. 7 CHAIRMAN KLEIN: WE HOPE TO REJOIN THE PUBLIC SESSION IN ABOUT AN HOUR. AND WHO JUST JOINED? 8 9 MS. FEIT: MARCY FEIT. 10 CHAIRMAN KLEIN: GREAT, MARCY. 11 MS. KING: HI, MARCY. GREAT. THANK YOU. 12 CHAIRMAN KLEIN: MARCY, WE'RE GOING INTO THE 13 CLOSED SESSION. AND IF YOU DON'T HAVE -- DO YOU HAVE THE 14 NUMBER? 15 MS. FEIT: YES, I DO. I HAVE THE CLOSED 16 SESSION NUMBER AND THE CODE. 17 CHAIRMAN KLEIN: OKAY. GREAT. SO WE WILL 18 ADJOURN INTO THE CLOSED SESSION, AND WE HOPE TO RECONVENE 19 IN BETWEEN AN HOUR AND HOUR AND A HALF. 20 MS. KING: THANKS, EVERYBODY. 21 (THE MEETING THEN ADJOURNED TO CLOSED 22 SESSION, NOT REPORTED, NOR HEREIN TRANSCRIBED. THE 23 MEETING WAS THEN RECONVENED AND HEARD AS FOLLOWS:) 24 MS. KING: OKAY. WE WILL NOW GO THROUGH THE 25 ROLL CALL VOTE.

6

1 CHAIRMAN KLEIN: WE ARE CONVENING THE PUBLIC 2 SESSION. WE HAVE THE DISTINCT PRIVILEGE TODAY, THIS 3 AFTERNOON IN CALIFORNIA, TOMORROW MORNING IN AUSTRALIA, 4 OF HAVING DR. ALAN TROUNSON. DIRECTOR OF THE MONASH 5 INSTITUTE FOR STEM CELL RESEARCH. DR. TROUNSON HAS 6 AGREED THAT IF THIS BOARD WERE TO VOTE HIM TO BE THE NEXT PRESIDENT OF THIS AGENCY, THAT HE WOULD GIVE UP HIS 7 8 LABORATORY, MOVE TO CALIFORNIA, HAVE THIS BE HIS 9 FULL-TIME JOB.

10 AND IT IS AT THIS POINT IN THE PUBLIC MEETING 11 APPROPRIATE TO EMPHASIZE THAT WE HAVE BEEN THROUGH A 12 LARGE NUMBER OF CANDIDATE INTERVIEWS, A TREMENDOUS 13 DEDICATED PROCESS THAT WE'RE DEEPLY APPRECIATIVE FOR THE 14 STAFF ASSISTANCE, FOR THE CANDIDATES' COMMITMENTS, AND 15 FOR THE BOARD.

16 WE ARE AT A HISTORICAL POINT OF SELECTING A 17 PRESIDENT, AND I BELIEVE, JEFF SHEEHY, YOU WERE 18 INTERESTED IN MAKING THE MOTION.

MR. SHEEHY: YES. I'D LIKE TO MOVE TO WE APPOINT DR. ALAN TROUNSON AS THE PERMANENT PRESIDENT OF THE CALIFORNIA INSTITUTE OF REGENERATIVE MEDICINE WITH THE -- COULD WE HAVE JAMES PERHAPS READ THE TERMS, OR YOU WANT ME TO READ THE TERMS, OR DO YOU WANT TO READ THE TERMS?

25 CHAIRMAN KLEIN: YOUR CHOICE.

7

MR. SHEEHY: IT WOULD BE BETTER TO LET JAMES
 JUST TO MAKE SURE I GET IT RIGHT.

CHAIRMAN KLEIN: THAT'S GREAT. SO THE REQUEST
IS THAT, JAMES HARRISON, IF YOU WILL READ THE PROPOSED
TERMS OF EMPLOYMENT.

6 MR. HARRISON: I'D BE HAPPY TO. THE TERMS OF 7 THE OFFER WOULD BE AS FOLLOWS: DR. TROUNSON WOULD BE 8 APPOINTED AT A SALARY NOT TO EXCEED \$490,000 PER YEAR; 9 AND DEPENDING UPON DEPARTMENT OF FINANCE APPROVAL OF 10 DR. TROUNSON'S RELOCATION EXPENSES, THAT SALARY MAY BE 11 REDUCED.

12 CHAIRMAN KLEIN: TO BE PRECISE, JAMES, IF HIS 13 RELOCATION EXPENSES ARE PAID, AS IS THE DESIRE OF THE 14 AGENCY, HIS SALARY WOULD BECOME 475,000. IT IS ONLY IF 15 HE HAS -- HIS BASIC SALARY IS 475, AND ITS ONLY 490,000 16 IF HE DOES NOT HAVE THOSE RELOCATION COSTS REIMBURSED.

17 MR. HARRISON: THAT'S CORRECT.

18 DR. TROUNSON, OF COURSE, WOULD BE EXPECTED TO 19 DEVOTE HIS FULL TIME AND EFFORTS TO HIS POSITION AS 20 PRESIDENT OF THE CIRM, WHICH MEANS THAT HE WILL NOT 21 MAINTAIN A LAB WHILE HE ACTS AS PRESIDENT; HOWEVER, IN 22 RECOGNITION OF THE FACT THAT HE WILL HAVE TO TRANSITION 23 HIS EXISTING LAB AND GRANTS TO HIS COLLEAGUES IN 24 AUSTRALIA, WE ARE WILLING TO ACCOMMODATE THAT BY OFFERING 25 TO LET DR. TROUNSON WORK ON A PART-TIME BASIS DURING THE

8

FIRST SIX MONTHS OF HIS EMPLOYMENT, IF IT'S NECESSARY TO
 DO SO, IN ORDER TO TRANSITION HIS LAB. AND, OF COURSE,
 THAT WOULD BE AT A PRORATED SALARY.

4 CHAIRMAN KLEIN: AND DURING THAT TIME PERIOD,
5 DR. MURPHY, WHO IS THERE NOW, WOULD CONTINUE TO BE THERE
6 FOR THE TRANSITION.

7 MR. HARRISON: THAT'S CORRECT. WE WOULD EXPECT 8 DR. TROUNSON TO BEGIN WORK AT THE INSTITUTE WITHIN 120 9 DAYS SUBJECT TO ANY NECESSARY ADDITIONAL TIME WE MIGHT 10 NEED IN ORDER TO OBTAIN A VISA ON HIS BEHALF, ALTHOUGH WE 11 DON'T ANTICIPATE ANY PROBLEMS IN THAT REGARD AT THIS 12 POINT IN TIME.

13 AS BOB MENTIONED EARLIER, WE WILL REQUEST THAT 14 THE DEPARTMENT OF FINANCE APPROVE DR. TROUNSON'S ACTUAL 15 RELOCATION EXPENSES FROM AUSTRALIA TO CALIFORNIA.

16 DR. TROUNSON, OF COURSE, AS AN EMPLOYEE OF THE CIRM, WILL 17 BE EXPECTED TO COMPLY AND HAS AGREED TO COMPLY WITH THE 18 CIRM'S CONFLICT OF INTEREST POLICY FOR EMPLOYEES, WHICH, 19 OF COURSE, REQUIRES THAT EMPLOYEES MAY NOT HOLD STOCK IN 20 A COMPANY THAT DEVOTES MORE THAN 5 PERCENT OF ITS

21 RESEARCH BUDGET TO STEM CELL RESEARCH.

OF COURSE, THOSE ARE THE ESSENTIAL TERMS. WE MAY NEED TO COME BACK TO THE BOARD SUBSEQUENT TO THIS POINT IN TIME TO REFINE THESE TERMS.

25 CHAIRMAN KLEIN: AND WHO WOULD LIKE TO MAKE THE

9

1 SECOND?

2

MR. GOLDBERG: MICHAEL GOLDBERG.

3 CHAIRMAN KLEIN: ALL RIGHT. MICHAEL GOLDBERG. 4 AND JEANNIE FONTANA IS THE SECOND SECOND FOR THE RECORD. 5 ADDITIONALLY, FOR THE BENEFIT OF THE PUBLIC, 6 I'D LIKE TO SAY THAT AUSTRALIA HAS A SPECIAL VISA STATUS 7 IN THE UNITED STATES, SOMETHING CALLED THE E3 VISAS. ALL 8 OF THOSE VISAS HAVE NOT BEEN USED FOR THE FISCAL YEAR, 9 AND THE NEW FISCAL YEAR STARTS OCTOBER 1ST, WHEN THERE 10 WILL BE A WHOLE NEW ALLOCATION. SO OUR LAWYER 11 REPRESENTING US ON THE VISA ISSUE HAS INDICATED THIS IS 12 NOT EXPECTED TO BE AN ISSUE BECAUSE OF THE PREVALENCE OF 13 THESE AND BECAUSE HE CLEARLY FITS THE CRITERIA. 14 AT THIS POINT, MICHAEL GOLDBERG, HAVING MADE 15 THE SECOND, OR JEFF SHEEHY, HAVING MADE THE MOTION, WOULD 16 YOU LIKE TO MAKE ANY COMMENTS FOR THE RECORD ABOUT THIS 17 MOTION? 18 MR. SHEEHY: WELL, I JUST THINK WE ARE 19 EXTREMELY FORTUNATE TO HAVE BEEN ABLE TO LAND SUCH AN 20 EXTRAORDINARY CANDIDATE WHO SEEMS TO HAVE MET ALL OF THE 21 DIFFERENT CONSIDERATIONS OF ALL THE DIFFERENT MEMBERS OF 22 THIS BOARD AND MATCHED UP PERFECTLY. HE'S A GLOBAL 23 LEADER IN STEM CELL RESEARCH, AND WE HOPE THAT HIS 24 EXPERTISE WILL BRING CURES AND THERAPIES TO THE PEOPLE OF 25 CALIFORNIA AS SOON AS POSSIBLE.

10

1	CHAIRMAN KLEIN: OKAY. MICHAEL GOLDBERG, DO
2	YOU HAVE ANY COMMENTS?
3	MR. GOLDBERG: IN ADDITION TO SECONDING WHAT
4	JEFF HAS SAID, I'VE BEEN EXTRAORDINARILY IMPRESSED WITH
5	HIS COMMITMENT TO TRANSLATIONAL RESEARCH, HIS HUMILITY AS
6	AN INDIVIDUAL, HIS EMPATHY FOR THOSE THAT ARE LESS
7	FORTUNATE, HIS COMMITMENT TO ESTABLISH THE CIRM AS THE
8	BEACON FOR STEM CELL RESEARCH GLOBALLY.
9	CHAIRMAN KLEIN: OKAY. ANY ADDITIONAL BOARD
10	COMMENTS BEFORE THE VOTE?
11	I'D JUST LIKE TO SAY THAT IT IS A GREAT
12	PRIVILEGE TO HAVE ALAN AS A CANDIDATE FOR THE PRESIDENCY.
13	IT IS A PHENOMENAL CAREER THAT HE HAS LED IN SCIENCE.
14	AND HAVING LED ONE REVOLUTION IN MAKING IN VITRO
15	FERTILIZATION POSSIBLE GLOBALLY, IT IS NOW REMARKABLE HIS
16	LEADERSHIP IN STEM CELL RESEARCH.
17	I'D LIKE TO OPEN IT TO ANY PUBLIC COMMENT
18	BEFORE THE VOTE.
19	MR. GOLDBERG: WE HAVE PUBLIC COMMENT AT OUR
20	SITE.
21	CHAIRMAN KLEIN: PLEASE LIMIT THE PUBLIC
22	COMMENT TO THREE MINUTES. JOHN SIMPSON AT OUR SITE HAS
23	PUBLIC COMMENT.
24	MR. SIMPSON: JOHN SIMPSON FROM THE FOUNDATION
25	FOR TAXPAYER AND CONSUMER RIGHTS. I AM WONDERFULLY
	11

1 IMPRESSED, COMPLETELY SURPRISED. SOME OF YOU MAY RECALL 2 THAT HE WAS ONE OF THE SCIENTISTS THAT WE SOUGHT OUT IN 3 SUPPORT OF OUR CHALLENGES OF THE WARF PATENTS AND SHARED 4 WITH YOU, WITH US, WHICH WE WERE DELIGHTED TO INCORPORATE 5 IN OUR FILINGS. AND I JUST THINK THAT THIS IS AN 6 EXCELLENT MOVE. I DON'T KNOW WHAT ELSE TO SAY ON THAT 7 SCORE.

8 WHEN I LOOKED AT YOUR AGENDAS, I MUST CONCEDE 9 THAT I HAD THOUGHT THAT YOU WOULD BE PAYING A LOT MORE ON 10 A HIGHER SALARY SIDE, WHICH AS AN ADVOCATE FOR THE 11 TAXPAYERS, I WAS DELIGHTED TO SEE THAT THIS SEEMED TO BE 12 A VERY FAIR AND EQUITABLE AND APPROPRIATE AMOUNT THAT 13 YOU'RE ATTACHING TO THIS OBVIOUSLY LEADING WORLDWIDE 14 RESEARCHER. I THINK IT'S JUST WONDERFUL THAT HE'S COMING 15 TO THE STATE OF CALIFORNIA.

16 (APPLAUSE.)

17CHAIRMAN KLEIN: ANY ADDITIONAL PUBLIC COMMENT?18MR. GOLDBERG: DON REED FROM NORTHERN

19 CALIFORNIA SITE.

20 MR. REED: YEAH. IT'S A GLORIOUS CHOICE. AS 21 AN ADVOCATE, NATURALLY WE FOLLOWED THE FIGHT IN AUSTRALIA 22 TO PROTECT SOMATIC CELL NUCLEAR TRANSFER. DR. TROUNSON 23 WAS AN ACKNOWLEDGED LEADER, AND HE HAD AN ABILITY TO 24 STATE THE SCIENTIFIC CASE CLEARLY AND THE HUMANITARIAN 25 CASE CLEARLY IN A NONINSULTING WAY SO THAT EVERYONE FELT

12

1	A PART OF THIS IMPORTANT DECISION. IT'S A BRILLIANT
2	CHOICE AND WE'RE JUST DELIGHTED.
3	I UNDERSTAND THE MORNING IS COMING UP IN
4	AUSTRALIA, AND THAT'S THE EMOTION WE ALL SHARE AT THIS
5	MOMENT. THANK YOU.
6	CHAIRMAN KLEIN: THANK YOU VERY MUCH. ANY
7	ADDITIONAL PUBLIC COMMENT? HEARING NONE, I WILL CALL FOR
8	THE ROLL TO BE CALLED.
9	MS. KING: RICARDO AZZIZ. ROBERT PRICE.
10	DR. PRICE: YES.
11	MS. KING: DAVID BRENNER.
12	DR. BRENNER: YES.
13	MS. KING: SUSAN BRYANT. MARSHA CHANDLER.
14	MARCY FEIT.
15	MS. FEIT: YES.
16	MS. KING: MICHAEL FRIEDMAN.
17	DR. FRIEDMAN: YES.
18	MS. KING: MICHAEL GOLDBERG.
19	MR. GOLDBERG: YES.
20	MS. KING: BRIAN HENDERSON.
21	DR. HENDERSON: YES.
22	MS. KING: DAVID KESSLER. BOB KLEIN.
23	CHAIRMAN KLEIN: YES.
24	MS. KING: SHERRY LANSING.

13

1	MS. KING: GERALD LEVEY.
2	DR. LEVEY: YES.
3	MS. KING: TED LOVE.
4	DR. LOVE: YES.
5	MS. KING: TINA NOVA. ED PENHOET.
6	DR. PENHOET: YES.
7	MS. KING: PHIL PIZZO.
8	DR. PIZZO: YES.
9	MS. KING: AND JUST FOR THE RECORD, DR. PIZZO
10	WAS ABLE TO JOIN US, BECAUSE, AS DR. PENHOET POINTED OUT,
11	STANFORD WAS PUBLICLY NOTICED. THANK YOU.
12	DR. CLAIRE POMEROY.
13	DR. POMEROY: YES.
14	MS. KING: FRANCISCO PRIETO.
15	DR. PRIETO: YES.
16	MS. KING: JEANNIE FONTANA.
17	DR. FONTANA: YES.
18	MS. KING: DUANE ROTH.
19	MR. ROTH: YES.
20	MS. KING: JOAN SAMUELSON.
21	MS. SAMUELSON: YES.
22	MS. KING: DAVID SERRANO-SEWELL. JEFF SHEEHY.
23	MR. SHEEHY: YES.
24	MS. KING: JONATHAN SHESTACK. OSWALD STEWARD.
25	DR. STEWARD: YES.

14

1	MS. KING: JANET WRIGHT.
2	DR. WRIGHT: YES.
3	CHAIRMAN KLEIN: SO LET ME ASK COUNSEL. DO WE
4	HAVE A QUORUM, COUNSEL?
5	MR. HARRISON: WE DO INDEED, AND THE MOTION
6	CARRIES UNANIMOUSLY.
7	(APPLAUSE.)
8	CHAIRMAN KLEIN: SO, DR. TROUNSON, WE ARE
9	EXTRAORDINARILY PRIVILEGED TO HAVE YOU AS OUR PERMANENT
10	PRESIDENT. WOULD YOU LIKE TO MAKE ANY STATEMENT?
11	DR. TROUNSON: IT'S VERY DIFFICULT. I THINK
12	IT'S A PRIVILEGE AND AN HONOR, AND I CAN'T THINK OF ANY
13	WAY ANY OTHER WAY THAT I'D LIKE TO SORT OF SEE MY
14	CAREER GO. I THINK THIS IS, IF YOU LIKE, A MAKER FOR MY
15	CAREER, BUT I ACTUALLY JUST WANT TO GET ON WITH THE JOB.
16	I WOULD VERY MUCH LIKE TO INTERACT WITH
17	EVERYBODY IN CALIFORNIA, BUT IN PARTICULAR ON THE
18	COMMITTEE, AND I'M LOOKING FORWARD TO WORKING WITH BOB
19	AND DR. MURPHY AND ALL THE STAFF THERE.
20	I THINK YOU'VE I'M OVERWHELMED REALLY, AND
21	I'M SORRY THAT THESE KIND OF THINGS DON'T HAPPEN OFTEN TO
22	US COLONIALS DOWN UNDER VERY OFTEN. IT IS IT'S
23	SOMETHING TO BE REALLY PROUD OF. AND I KNOW MY FAMILY
24	AND MY CHILDREN WILL THANK YOU VERY, VERY MUCH. IF MY
25	MOM AND DAD WERE AROUND, THEY WOULDN'T BELIEVE IT, THAT

15

1 ONE OF THEIR KIDS WAS ABLE TO GET TO SUCH A WONDERFUL 2 POSITION. I JUST THANK YOU VERY MUCH. YOU'RE VERY KIND 3 AND YOU'RE VERY GENEROUS, AND I HOPE I CAN DELIVER ON THE 4 VISION THAT YOU'VE CREATED. AND I'LL DO MY VERY BEST. 5 THANK YOU VERY MUCH. 6 CHAIRMAN KLEIN: OKAY. THANK YOU. 7 (APPLAUSE.) CHAIRMAN KLEIN: WHAT WE ARE GOING TO DO HERE 8 9 IS WE ADJOURN THE PUBLIC MEETING AT THIS TIME, AND THEN 10 WE WILL IMMEDIATELY GO INTO A PRESS CONFERENCE. SO AT 11 THOSE SITES WHERE THERE ARE PRESS, IF YOU WILL KEEP THOSE 12 LINES OPEN; BUT THE OTHER MEMBERS WHO ARE THERE, THERE'S 13 A PRESIDENTIAL SEARCH COMMITTEE FOLLOW-UP AFTER THIS, SO 14 WE'LL TRY AND KEEP THIS PRESS CONFERENCE TO A REASONABLY 15 LIMITED TIME IF WE CAN. SO JUST KEEP THESE LINES OPEN 16 AND GO DIRECTLY INTO THE PRESS CONFERENCE. THE ACTUAL 17 MEETING ITSELF IS ADJOURNED. 18 (THE MEETING WAS THEN ADJOURNED TO THE 19 PRESS CONFERENCE, NOT REPORTED NOR HEREIN TRANSCRIBED.) 20 21 22 23 24 25

16

### REPORTER'S CERTIFICATE

I, BETH C. DRAIN, A CERTIFIED SHORTHAND REPORTER IN AND FOR THE STATE OF CALIFORNIA, HEREBY CERTIFY THAT THE FOREGOING TRANSCRIPT OF THE PROCEEDINGS BEFORE THE INDEPENDENT CITIZEN'S OVERSIGHT COMMITTEE OF THE CALIFORNIA INSTITUTE FOR REGENERATIVE MEDICINE IN THE MATTER OF ITS TELEPHONIC MEETING ON FRIDAY, SEPTEMBER 14, 2007, WAS HELD AS HEREIN APPEARS AND THAT THIS IS THE ORIGINAL TRANSCRIPT THEREOF AND THAT THE STATEMENTS THAT APPEAR IN THIS TRANSCRIPT WERE REPORTED STENOGRAPHICALLY BY ME AND TRANSCRIBED BY ME. I ALSO CERTIFY THAT THIS TRANSCRIPT IS A TRUE AND ACCURATE RECORD OF THE PROCEEDING.

BETH C. DRAIN, CSR 7152 BARRISTER'S REPORTING SERVICE 1072 S.E. BRISTOL STREET SUITE 100 SANTA ANA HEIGHTS, CALIFORNIA (714) 444-4100

17